The FLOT Regimen Conversion Therapy of Adenocarcinoma of the Stomach / Gastroesophageal
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
Evaluate survival benefit of surgical treatment after FLOT regimen conversion therapy of
Her-2 Negative and single site metastasis adenocarcinoma of the stomach / gastroesophageal
compared with chemotherapy, use relevant biomarkers to evaluate the efficacy of chemotherapy
and seek for patients with Her-2 negative and metastatic adenocarcinoma of the stomach /
gastroesophageal surviving benefit from surgical treatment after the FLOT regimen conversion
therapy.